Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
MOLECULARLY TARGETED: MSI-h/dMMR: myTACTIC Arm E(2)

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors

Title
Genentech ML42439 (myTACTIC) MSI-h
Study Title

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors

Site Link
Malignancy
Any: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
Any, but cannot have had prior anti-PD-1 or anti-PD-L1
Investigational Agent
Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)
Drug Class
PD-L1 inhibitor + chemotherapy
PI
Sponsor
Genentech, Inc.
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically or cytologically confirmed advanced unresectable or metastatic solid malignancy
  • Positive biomarker results from a CLIA certified lab, either tissue or blood sample
  • Microsatellite instability high (MSI-h) or deficient mismatch repair dMMR
  • No prior treatment with anti-PD1 or anti-PD-L1 agents
  • ECOG PS 0-2
  • No symptomatic CNS metastases
  • No known HIV/HBV/HCV
  • No other malignancy within 3 years of study
  • No prior treatment with crizotinib
  • No active autoimmune disease
Objective
  • Primary-
    • ORR
  • Secondary
    • PFS
    • DoR
    • OS
    • PFS at various time points
    • DCR
    • Safety
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
MSI-h or dMMR
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X